엘이디 알람 기능을 갖는 가정용 화장품 진열대
    23.
    实用新型
    엘이디 알람 기능을 갖는 가정용 화장품 진열대 失效
    具有LED报警控制的化妆品显示单元

    公开(公告)号:KR200468346Y1

    公开(公告)日:2013-08-08

    申请号:KR2020120003944

    申请日:2012-05-11

    Abstract: 본 고안은 요일별로 램프의 발광시간 및 횟수를 세팅시킨후 요일마다 별도로 점등되어 사용해야할 화장품을 알려주고 아울러 세팅된 시간 및 횟수가 끝나면 소등되도록 한 것을 특징으로 하는 엘이디 알람 기능을 갖는 가정용 화장품 진열대에 관한 것으로,
    한개 이상의 삽입홈이 형성된 화장품 진열용 케이스와; 상기 삽입홈에 형성되는 조명수단과; 상기 삽입홈의 내측하단에 설치되는 무게 감지수단과; 상기 화장품 진열용 케이스의 측면에 형성되며, 화장품의 요일선택 및 사용 횟수 선택을 위한 정보 입력수단과; 상기 입력수단과, 무게감지수단과, 조명수단에 전기적으로 연결되며, 입력수단으로부터 요일별 및 횟수별 정보를 입력받아 메모리하고, 무게감지수단으로부터 화장품의 존재유무를 파악함과 동시에 화장품이 삽입홈로부터 인출되는 횟수를 파악하며, 입력수단으로부터 입력된 요일이 되면 해당 번호의 조명수단를 점등시키고 사용자가 삽입홈로부터 화장품을 인출하면 조명수단를 소등하며, 삽입홈으로 입력하면 다시 해당 번호를 점등하되 해당횟수만큼 화장품의 사용이 마무리되면 엘이디를 소등시키도록 제어하는 제어수단 및; 상기 조명수단에 전원을 공급하기 위한 전원공급수단을 포함하여 구성함이 특징이다.

    밤껍질 추출물을 포함하는 화장료 조성물
    24.
    发明公开
    밤껍질 추출물을 포함하는 화장료 조성물 有权
    化妆品组合包括CHESTNUT壳提取物

    公开(公告)号:KR1020120027436A

    公开(公告)日:2012-03-21

    申请号:KR1020117031696

    申请日:2010-06-18

    CPC classification number: A61Q19/005 A61K8/97 A61K36/49

    Abstract: PURPOSE: A cosmetic composition containing nutshell extract is provided to suppress proteinase-activated receptor-2(PAR-2) and to relieve itching. CONSTITUTION: A cosmetic composition for relieving or suppressing itching contains nutshell extract as an active ingredient. The composition prevents or relieves itching caused by inflammatory dermatitis, atopic dermatitis, miliaria, frostbite, contact dermatitis, seborrheic dermatitis, or pruritus. A cosmetic composition improving skin barrier function contains the nutshell extract as an active ingredient. The extract is prepared using water, low alcohol of C1-4, 1,3-butylene glycol, or mixture thereof.

    Abstract translation: 目的:提供含有坚果壳提取物的化妆品组合物,以抑制蛋白酶激活的受体-2(PAR-2)并缓解瘙痒。 构成:用于缓解或抑制瘙痒的化妆品组合物含有坚果壳提取物作为活性成分。 该组合物预防或缓解由炎症性皮炎,特应性皮炎,睫毛膏,冻伤,接触性皮炎,脂溢性皮炎或瘙痒引起的瘙痒。 改善皮肤屏障功能的化妆品组合物含有坚果壳提取物作为活性成分。 提取物是使用C 1-4,1,3-丁二醇或其混合物的水,低级醇制备的。

    2-사이클로펜텐-1-온 옥심 유도체를 유효성분으로 포함하는 지방대사질환 예방 및 치료용 약학 조성물
    27.
    发明公开
    2-사이클로펜텐-1-온 옥심 유도체를 유효성분으로 포함하는 지방대사질환 예방 및 치료용 약학 조성물 有权
    用于预防或治疗含有2-环戊烯-1-酮氧化衍生物的脂肪代谢相关疾病的药物组合物

    公开(公告)号:KR1020100103671A

    公开(公告)日:2010-09-27

    申请号:KR1020107017557

    申请日:2008-12-03

    CPC classification number: A61K31/15

    Abstract: PURPOSE: A pharmaceutical composition containing 2-cyclopentene-1-one oxime derivative is provided to promote adipose lysis in adipocytes(3T3-L1) and to prevent and treat lipid metabolic diseases including obesity and diabetes. CONSTITUTION: A pharmaceutical composition for preventing and treating lipid metabolic diseases contains 2-cyclopenten-1-one oxime derivative compound of chemical formula 1 or pharmaceutically acceptable salt thereof as an active ingredient. In chemical formula 1, R1 is linear or branched C1-C10 alkyl group or C3-C7 cycloalkyl group, or phenyl group with or without substituent. The phenyl group is denoted by chemical formula 2. The pharmaceutical composition is used for preventing and treating obesity, diabetes, or dyslipidemia.

    Abstract translation: 目的:提供含有2-环戊烯-1-酮肟衍生物的药物组合物,以促进脂肪细胞(3T3-L1)中的脂肪裂解,并预防和治疗脂肪代谢疾病,包括肥胖和糖尿病。 构成:用于预防和治疗脂质代谢疾病的药物组合物含有化学式1的2-环戊烯-1-酮肟衍生物化合物或其药学上可接受的盐作为活性成分。 在化学式1中,R 1为直链或支链C 1 -C 10烷基或C 3 -C 7环烷基,或具有或不具有取代基的苯基。 苯基由化学式2表示。药物组合物用于预防和治疗肥胖症,糖尿病或血脂异常。

    바닐로이드 수용체 길항제로 작용하는 신규 화합물, 이의 이성질체 또는 이의 약제학적으로 허용 가능한 염 및 이를 포함하는 약학 조성물
    28.
    发明公开
    바닐로이드 수용체 길항제로 작용하는 신규 화합물, 이의 이성질체 또는 이의 약제학적으로 허용 가능한 염 및 이를 포함하는 약학 조성물 有权
    新型化合物,异构体或其药学上可接受的盐作为VANULLOID受体拮抗剂和含有其的药物组合物

    公开(公告)号:KR1020100053470A

    公开(公告)日:2010-05-20

    申请号:KR1020090108632

    申请日:2009-11-11

    Abstract: PURPOSE: A novel compound which functions as a vanilloid receptor 1(VR1) antagonist is provided to prevent or treat disease related to hair growth, rhinitis, and pancreatitis. CONSTITUTION: A vanilloid receptor antagonist compound is denoted by chemical formula I. A pharmaceutical composition contains the compound, isomer, or pharmaceutically acceptable salt thereof. The composition is used for preventing or treating arthritis disease, neuropathy, HIV related neuropathy, nerve injury, neurodegeneration, cerebral apoplexy, urinary incontinence, cough, neuropathy/allergy/inflammation skin disease, atopic dermatitis, psoriasis, pruritus, the prurigo, acouesthesia, aliasing, bregma anaphylaxis, effluvium, or alopecia.

    Abstract translation: 目的:提供作为香草素受体1(VR1)拮抗剂起作用的新型化合物,以预防或治疗与毛发生长,鼻炎和胰腺炎有关的疾病。 构成:香草素受体拮抗剂化合物由化学式I表示。药物组合物含有化合物,异构体或其药学上可接受的盐。 该组合物用于预防或治疗关节炎疾病,神经病,HIV相关神经病,神经损伤,神经变性,脑中风,尿失禁,咳嗽,神经病变/过敏/炎症皮肤病,特应性皮炎,牛皮癣,瘙痒,瘙痒症,麻醉, 混叠,原发性过敏性反应,流出或脱发。

    옹기를 구비하는 추출기 및 추출 방법
    29.
    发明公开
    옹기를 구비하는 추출기 및 추출 방법 有权
    有萃取剂和提取方法

    公开(公告)号:KR1020090054736A

    公开(公告)日:2009-06-01

    申请号:KR1020070121572

    申请日:2007-11-27

    CPC classification number: A47J31/32

    Abstract: An extractor and an extracting method using a pottery are provided to create high pressure inside the extractor body in order to prevent extracts from contacting the extractor body of metal material. An extractor(200) comprises a hollow body(210) made of metal, a cover(220) closing the body, a heating part(230) heating the body from the outside, a pottery(240) placed inside the body, and a gas valve(250) which injects gas into the body or discharges gas from the body.

    Abstract translation: 提供使用陶器的提取器和提取方法以在提取器体内产生高压,以防止提取物与金属材料的提取体接触。 提取器(200)包括由金属制成的中空体(210),封闭主体的盖(220),从外部加热身体的加热部(230),放置在身体内的陶器(240),以及 气体阀(250),其将气体注入体内或从身体排出气体。

    바닐로이드 수용체 길항물질로서의 신규 화합물, 이의이성체 또는 이의 약학적으로 허용가능한 염, 및 이를함유하는 약학 조성물
    30.
    发明公开
    바닐로이드 수용체 길항물질로서의 신규 화합물, 이의이성체 또는 이의 약학적으로 허용가능한 염, 및 이를함유하는 약학 조성물 有权
    新化合物,其异构体,或其药学上可接受的盐作为VANILLOID受体拮抗剂; 和含有它们的药物组合物

    公开(公告)号:KR1020080007329A

    公开(公告)日:2008-01-18

    申请号:KR1020077024002

    申请日:2006-03-15

    Abstract: A compound as a vanilloid receptor antagonist is provided to obtain a pharmaceutical composition effective for preventing or treating pain, migraine, arthralgia, nerve injury, skin diseases, overactive bladder, irritable bowel syndrome, or the like. A compound as a vanilloid receptor antagonist, an isomer or a pharmaceutically acceptable salt thereof is represented by the following formula I. In formula I, X is NHCH2, CR11=CR12, NH, CHR11CHR12 or C=C, wherein each of R11 and R12 represents H, halogen, C1-C5 alkyl, C1-C5 alkoxy, halo(C1-C5)alkyl or phenyl; R1 is a C2-C5 alkenyl or C2-C5 alkynyl; R2 is H, halogen, nitro, cyano, C1-C5 alkyl, C1-C5 alkoxy, halo(C1-C5)alkyl, C2-C5 alkenyl, or C2-C5 alkynyl; R2 is H, halogen, nitro, cyano, C1-C5 alkyl, C1-C5 alkoxy, halo(C1-C5)alkyl, C2-C5 alkenyl, C2-C5 alkynyl, carboxyl, C1-C5 alkoxycarbonyl, C1-C5 alkylthio, phenyl or phenyl(C1-C3)alkyl, wherein is each phenyl group is non-substituted or substituted with at least one substituent; R3 is H, C1-C5 alkyl, C1-C5 alkoxy or halo(C1-C5)alkyl; each of R4, R5 R6, R7 and R8 independently represents H, carboxyl, C1-C5 alkyl, nitro, C2-C5 alkenyl, C1-C5 alkoxy, C2-C5 alkynyl, halo(C1-C5)alkyl, C1-C5 alkylthio, C1-C5 alkylsulfonyl, C1-C5 alkylcarbonyl, C1-C5 alkoxycarbonyl, hydroxy, C2-C5 alkenyloxy, C1-C5 alkoxy(C1-C5)alkoxy, C1-C5 alkoxy(C1-C5)alkoxy(C1-C5)alkyl, C1-C3 alkylpiperazinyl, piperazinyl(C1-C5)alkoxy, piperidinyl(C1-C5)alkoxy, C1-C5 alkoxy (C1-C5)alkylamino, C1-C7 alkylamino, morpholinyl, morpholinyl(C1-C5)alkyloxy, tetrahydropyranyloxy, phenyl or halogen, wherein each phenyl group is non-substituted or substituted with at least one substituent; each of R9 and R10 independently represents H, -SO2R13, -SOR13, C1-C5 alkyl, C1-C5 alkoxy, halo (C1-C5)alkyl, C2-C5 alkenyl, C1-C5 alkoxycarbonyl, C1-C5 alkylthio, phenyl or phenyl (C1-C3)alkyl, wherein each phenyl group is non-substituted or substituted with at least one substituent, and R13 is H, amino, C1-C5 alkyl, C2-C5 alkenyl, C1-C5 alkoxy, halo(C1-C5)alkyl, trifluoromethyl, phenyl or phenyl(C1-C3)alkyl.

    Abstract translation: 提供作为香草素受体拮抗剂的化合物以获得有效预防或治疗疼痛,偏头痛,关节痛,神经损伤,皮肤疾病,膀胱过度活动症,肠易激综合征等的药物组合物。 作为香草酸受体拮抗剂的化合物,其异构体或其药学上可接受的盐由下式I表示。在式I中,X为NHCH 2,CR 11 = CR 12,NH,CHR 11 CHR 12或C = C,其中R 11和R 12 表示H,卤素,C 1 -C 5烷基,C 1 -C 5烷氧基,卤代(C 1 -C 5)烷基或苯基; R1是C2-C5烯基或C2-C5炔基; R2是H,卤素,硝基,氰基,C1-C5烷基,C1-C5烷氧基,卤代(C1-C5)烷基,C2-C5烯基或C2-C5炔基; R2是H,卤素,硝基,氰基,C1-C5烷基,C1-C5烷氧基,卤代(C1-C5)烷基,C2-C5烯基,C2-C5炔基,羧基,C1-C5烷氧羰基,C1-C5烷硫基, 苯基或苯基(C1-C3)烷基,其中每个苯基是未取代的或被至少一个取代基取代; R3是H,C1-C5烷基,C1-C5烷氧基或卤代(C1-C5)烷基; R 4,R 5,R 6,R 7和R 8各自独立地表示H,羧基,C 1 -C 5烷基,硝基,C 2 -C 5烯基,C 1 -C 5烷氧基,C 2 -C 5炔基,卤代(C 1 -C 5)烷基,C 1 -C 5烷硫基 ,C1-C5烷基磺酰基,C1-C5烷基羰基,C1-C5烷氧基羰基,羟基,C2-C5链烯氧基,C1-C5烷氧基(C1-C5)烷氧基,C1-C5烷氧基(C1-C5)烷氧基(C1-C5)烷基 (C1-C5)烷氧基,C1-C5烷氧基(C1-C5)烷基氨基,C1-C7烷基氨基,吗啉基,吗啉基(C1-C5)烷氧基,四氢吡喃基氧基, 苯基或卤素,其中每个苯基未被取代或被至少一个取代基取代; R 9和R 10各自独立地表示H,-SO 2 R 13,-SOR 13,C 1 -C 5烷基,C 1 -C 5烷氧基,卤代(C 1 -C 5)烷基,C 2 -C 5烯基,C 1 -C 5烷氧基羰基,C 1 -C 5烷硫基,苯基或 苯基(C1-C3)烷基,其中每个苯基未被取代或被至少一个取代基取代,R 13是H,氨基,C 1 -C 5烷基,C 2 -C 5烯基,C 1 -C 5烷氧基,卤代(C1- C5)烷基,三氟甲基,苯基或苯基(C1-C3)烷基。

Patent Agency Ranking